In adults with T2D and clinical ASCVD, who are in use of either SGLT2i or a GLP-1 RA, combining GLP-1 RA plus SGLT2i MAY BE CONSIDERED, as it is associated with fewer CV events and decreased all-cause mortality. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.